|
Match
|
Document |
Document Title |
|
|
US20090306396 |
NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient....
|
|
|
US20090306156 |
PHOSPHODIESTERASE 4 INHIBITORS
Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I:
wherein R 1 , R 2 , and...
|
|
|
US20090286980 |
OPTICALLY ACTIVE 3-AMINO-2,5-DIOXOPYRROLIDINE-3-CARBOXYLATE, PROCESS FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND
The present invention provides a compound of the formula (III):
wherein R is a C 1-6 alkyl group,
as a novel optically active intermediate for preparing...
|
|
|
US20090281161 |
Organic Compounds
Novel 3,4-di-, 3,3,4-di-, 3,4,4,-tri- and 3,3,4,4-tetra-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially...
|
|
|
US20090270417 |
Organic Compounds
Novel 3,4-di-, 3,3,4-di-, 3,4,4,-tri- and 3,3,4,4-tetra-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially...
|
|
|
US20090247503 |
5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF
Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities...
|
|
|
US20090239866 |
PEPTIDE DEFORMYLASE INHIBITORS
Novel PDF inhibitors and novel methods for their use are provided.
|
|
|
US20090239867 |
THERAPEUTIC SUBSTITUTED GAMMA LACTAMS
Disclosed herein is a compound comprising
or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related...
|
|
|
US20090227635 |
THERAPEUTIC COMPOUNDS
Compounds comprising
or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, B, and J are as described. Methods, compositions, and medicaments related thereto...
|
|
|
US20090221839 |
Preparation of an Atorvastatin Intermediate
Atorvastatin lactone is prepared by hydrogenating tert-butyl isopropylidene nitrile to tert-butyl isopropylidene amine and condensing the amine with the diketone of atorvastatin to form acetonide...
|
|
|
US20090186834 |
DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS
Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using...
|
|
|
US20090176836 |
Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
The present invention is directed to cyclic ketal compounds of formula (I)
which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the...
|
|
|
US20090118298 |
Octahydropentalene compounds as chemokine receptor antagonists
The present invention is directed to novel compounds of Formula (I)
pharmaceutically acceptable salts thereof, pro-drugs thereof, biologically active metabolites thereof, isomers thereof or...
|
|
|
US20090062553 |
Process and Intermediates Useful in the Preparation of Statins, Particularly Atorvastatin
There is provided a process for the preparation of a compound of formula (7) or salts thereof: wherein R 1 represents a hydrogen or a hydrocarbyl group, R 2 represents a hydrogen or substituent...
|
|
|
US20090012148 |
REDUCING CELLULAR CHOLESTEROL LEVELS AND/OR TREATING OR PREVENTING PHOSPHOLIPIDOSIS
Compounds disclosed herein may be used in disclosed methods for reducing the amount of cholesterol in a cell, for treating a patient suffering from a disorder characterized by cellular accumulation...
|
|
|
US20080292587 |
OXIMYL DIPEPTIDE HEPATITIS C PROTEASE INHIBITORS
The present invention discloses compounds of formulae I, or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit serine protease activity, particularly the activity of...
|
|
|
US20080262246 |
3-Alkyl-5- (4-Alkyl-5-Oxo-Tetrahydrofutr An -2-Yl) Pyrrolidin-2-One Derivatives As Intermediates In The Synthesis Of Renin Inhibitors
The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren....
|
|
|
US20080255220 |
Therapeutic Substituted Gamma Lactams
Disclosed herein is a compound comprising
or a pharmaceutically acceptable salt or a prodrug thereof;
wherein Y, A, X, R and D are as described.
Methods, compositions, and medicaments related...
|
|
|
US20080227806 |
Novel Drugs for Dementia
The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain...
|
|
|
US20080220286 |
Dinaphthyl ethylene derivativce, process for preparing it, film prepared from it, and OLED including the film
The present invention relates to a dinaphthyl ethylene derivative of formula (I), a process for preparing it, a film prepared from it useful in the manufacure of an organic light emitting device...
|
|
|
US20080176841 |
EPOXIDE INHIBITORS OF CYSTEINE PROTEASES
Provided herein are novel epoxide inhibitors of cysteine proteases, compositions comprising the epoxide inhibitors, and packaged pharmaceuticals. Also provided are methods of inhibiting a...
|
|
|
US20080171734 |
CHEMICAL COMPOUNDS
The invention relates to a novel group of compounds of Formula (I) or a salt thereof:
wherein R 1 , A and HET-1 are as described in the specification, which may be useful in the treatment or...
|
|
|
US20080146818 |
Bicycloester Derivative
Novel bicycloester derivatives and pharmaceutically acceptable salts thereof have high DPP-IV inhibitory activity. SOLVING MEANS The novel bicycloester derivatives are represented by the general...
|
|
|
US20080132503 |
Inhibitors of Histone Deacetylase
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides...
|
|
|
US20080114030 |
Diarymethyl and related compounds
This invention provides compounds of formula I:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Ar 1 , Ar 2 , E, a, b, c and z are as defined in the specification, or a pharmaceutically...
|
|
|
US20080114051 |
PYRROLIDINE DERIVATIVES AS PROSTAGLANDIN MODULATORS
Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful...
|
|
|
US20080070972 |
Controlled release formulations
The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.
|
|
|
US20080064695 |
PYRROLE DERIVATIVES AND THEIR METHODS OF USE
The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.
|
|
|
US20080051575 |
PHOTOCHROMIC COMPOUNDS
Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other...
|
|
|
US20080045489 |
3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
Disclosed are novel cyclobutenedione Compounds 1 to 18 comprising a cyclobutenedione ring, a substituted phenyl ring, and a —CH(C 2 H 5 )-furan moiety. The phenyl ring and the —CH(C 2 H 5...
|
|
|
US20080045704 |
PHOTOCHROMIC COMPOUNDS
Various non-limiting embodiments disclosed herein relate generally to photochromic compounds, which may be thermally reversible or non-thermally reversible, and articles made therefrom. Other...
|
|
|
US20080045560 |
Pyrrolidine and related derivatives useful as PR modulators
Compounds of the following structure are described:
wherein R 1 -R 6 , R 11 , R 12 , m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or...
|
|
|
US20080039505 |
THERAPEUTIC LACTAMS
Disclosed herein is a compound having a structure
Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
|
|
US20080033023 |
THERAPEUTIC COMPOUNDS
Disclosed herein is a compound having a structure
or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also...
|
|
|
US20080004330 |
Aminomethyl-Azacycle Derivatives as Inhibitors of Monoamine Uptake
The present invention provides compounds of formula (I) wherein A is (1), (2), (3), (4), (5), (6) or (7) and wherein R1, R7, y and Ar 1 are defined herein. The compounds are inhibitors of the...
|